China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received approval from the US FDA to commence a clinical study for its bispecific fusion protein, JMT106, targeting GPC3-positive solid tumors.
JMT106 is designed to target both GPC3 and interferon receptors, aiming to elicit antibody-dependent cellular cytotoxicity (ADCC) while activating the immune response within the tumor microenvironment. GPC3 is notably overexpressed in several solid tumors, including hepatocellular carcinoma, squamous cell lung carcinoma, and ovarian cancer. Preclinical studies have demonstrated that JMT106 exhibits significant anti-tumor effects and a favorable safety profile in models of liver, lung, and ovarian cancers, positioning it as a promising candidate in the oncology pipeline.- Flcube.com
